Globe Newswire07.31.18
IRIDEX Corporation has received approval of its CYCLO G6 Glaucoma Laser system by South Korea's Ministry of Food and Drug Safety (MFDS). Currently available in more than 50 countries, the CYCLO G6 treats patients diagnosed with a range of glaucoma disease states using the company’s proprietary MicroPulse technology and a family of single-use probes.
“International expansion in the Asia-Pacific region remains a top priority for us and we believe that Korea represents an attractive market opportunity for our G6 technology,” said William M. Moore, president and CEO. “We set G6 approval in Korea as a key target for our 2018 expansion strategy and I am delighted to have reached this key milestone. Importantly, we have already started to garner feedback and support from key opinion leaders in the region and expect to leverage their support in our launch strategy.”
The CYCLO G6 platform is supported by a growing body of clinical evidence and extensive validation in the field for the treatment of glaucoma. Physicians worldwide have adopted the G6 because it is safe, minimally invasive, non-incisional, repeatable and durable, according to the company. Moreover, the G6 provides physicians and the healthcare system a cost-effective solution for the treatment of glaucoma across the full continuum of care—from early stage to late stage glaucoma.
"We believe these tangible reasons are driving increased awareness and excitement in the worldwide glaucoma community for our G6. We look forward to continued success accelerating CYCLO G6 adoption and utilization,” concluded Moore.
IRIDEX Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema, and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. www.iridex.com
“International expansion in the Asia-Pacific region remains a top priority for us and we believe that Korea represents an attractive market opportunity for our G6 technology,” said William M. Moore, president and CEO. “We set G6 approval in Korea as a key target for our 2018 expansion strategy and I am delighted to have reached this key milestone. Importantly, we have already started to garner feedback and support from key opinion leaders in the region and expect to leverage their support in our launch strategy.”
The CYCLO G6 platform is supported by a growing body of clinical evidence and extensive validation in the field for the treatment of glaucoma. Physicians worldwide have adopted the G6 because it is safe, minimally invasive, non-incisional, repeatable and durable, according to the company. Moreover, the G6 provides physicians and the healthcare system a cost-effective solution for the treatment of glaucoma across the full continuum of care—from early stage to late stage glaucoma.
"We believe these tangible reasons are driving increased awareness and excitement in the worldwide glaucoma community for our G6. We look forward to continued success accelerating CYCLO G6 adoption and utilization,” concluded Moore.
IRIDEX Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema, and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. www.iridex.com